Takeda Pharmaceutical (NYSE:TAK) Insider Agosti Marcello Pignagnoli Sells 22,957 Shares of Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Agosti Marcello Pignagnoli sold 22,957 shares of Takeda Pharmaceutical stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $392,564.70. Following the sale, the insider directly owned 176,977 shares of the company’s stock, valued at $3,026,306.70. This trade represents a 11.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock opened at $17.42 on Thursday. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $18.90. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The firm has a market cap of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08. The stock’s 50-day moving average is $16.49 and its two-hundred day moving average is $17.13.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The company had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. Analysts predict that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current year.

Wall Street Analyst Weigh In

TAK has been the topic of several research reports. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in TAK. Private Trust Co. NA increased its position in Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after purchasing an additional 783 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Takeda Pharmaceutical by 192.2% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after purchasing an additional 1,684 shares during the period. SHP Wealth Management acquired a new position in shares of Takeda Pharmaceutical in the 4th quarter valued at about $42,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Takeda Pharmaceutical by 313.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after purchasing an additional 2,328 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in shares of Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after purchasing an additional 1,292 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Key Takeda Pharmaceutical News

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Insiders continued to hold substantial positions after the transactions, suggesting the sales do not necessarily reflect a loss of confidence in Takeda’s business or outlook. The filings state that the shares were sold to cover tax withholding obligations related to vested equity awards. SEC insider filing
• Neutral Sentiment: Analyst sentiment remains mixed: ratings include two Buys, one Hold and one Sell, resulting in an overall “Hold” consensus. Recent institutional buying has also provided some support, but those purchases were relatively small compared with Takeda’s market capitalization. Takeda stock analysis
• Negative Sentiment: Multiple senior executives and insiders sold a combined 399,? shares at an average price of $17.10. CEO Julie So-Young Kim sold 89,090 shares, Andrew Stewart Plump sold 165,393 shares and General Counsel Natalie Anne Marie Furney sold 30,868 shares. Other insiders also reduced their holdings by approximately 5.9% to 17.8%, which could weigh on investor sentiment despite the tax-related explanation. Takeda insider sales report

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.